Inactive Instrument

Hamlet Pharma AB (publ)

Equities

HAMLET B

SE0015661152

Hamlet Newsletter: Important steps forward towards treating bladder cancer

February 01, 2022 at 02:32 am EST

Hamlet-Pharma-Newsletter-Dose-escalationDownload

Attachments

Original Link
Original Document
Permalink

Disclaimer

Hamlet Pharma AB published this content on 01 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 February 2022 07:31:04 UTC.

Latest news about Hamlet Pharma AB (publ)

Hamlet BioPharma AB Completes the First Part of A Controlled Clinical Trial in Patients with Bladder Pain Syndrome (Severe Pain in the Urinary Bladder)	May. 06	CI
Hamlet BioPharma Secures Large Scale Alpha1 Peptide Production in an Agreement with Polypeptide Group	Apr. 18	CI
Hamlet BioPharma Announces Commercial Collaborations with Top International Advisory Firms	Apr. 11	CI
Hamlet BioPharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 22	CI
Hamlet Biopharma Announces New Analyses of Clinical Data from Alpha1h Treated Patients with Bladder Cancer Detect A Strong Immune Response with Known Anti-Tumor Effects	Jan. 25	CI
Hamlet Biopharma AB Announces Antimicrobial Peptide Therapy for Tuberculosis Infections	Dec. 20	CI
Hamlet Biopharma's Continued Development of Brain Tumor Therapy	Dec. 06	CI
Hamlet BioPharma Receives U.S. FDA Fast Track Designation for Alpha 1H for the Treatment of Non-Muscle Invasive Bladder Cancer	Nov. 29	CI
Hamlet BioPharma AB Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 17	CI
Hamlet BioPharma AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	23-08-28	CI
Hamlet BioPharma AB Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-28	CI
Hamlet Pharma Announces FDA Clearance of IND Application for Alpha1H for the Treatment of Non-Muscle Invasive Bladder Cancer	23-07-01	CI
Hamlet Pharma Announces CEO Changes	23-06-30	CI
Hamlet Pharma Secures Long-Term Alpha1 Peptide Production in an Agreement with Polypeptide Group	23-06-12	CI
Hamlet Pharma Secures New Alpha1H Production Batch for Continued Clinical Trials	23-05-31	CI
Hamlet Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-26	CI
Hamlet BioPharma AB (NGM:HAMLET B) completed the acquisition of Selectimmune Pharma AB.	23-05-16	CI
Hamlet Pharma's Bladder Cancer Project Set for EU Commission's Full Funding	23-04-14	MT
Hamlet Pharma to Merge with SelectImmune; Shares Down 10%	23-03-31	MT
Hamlet Pharma AB (NGM:HAMLET B) agreed to acquire Selectimmune Pharma AB (NGM:SELECT B).	23-03-30	CI
Hamlet Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-23	CI
Hamlet Pharma AB Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-11	CI
Hamlet Pharma AB Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-26	CI
Hamlet Pharma AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2022	22-08-26	CI
Hamlet Pharma Adapts the Clinical Trial Program for Stand-Alone Use	22-08-02	CI

Chart Hamlet Pharma AB (publ)

Duration

Period

More charts

Company Profile

Hamlet Pharma AB is a Sweden-based company that develops cancer therapeutics. The Company develops cancer therapeutics based on research into protein complexes that selectively induce cell-death in tumours. HAMLET, which stands for Human Alpha-lactalbumin Made LEthal to Tumours, is a protein-fatty acid complex derived from human milk. The complex induces apoptosis in tumour cells while leaving normal cells unaffected. In laboratory experiments, HAMLET is active against many different types of tumour cells, and uses several mechanisms to trigger cell death. HAMLET is also being evaluated clinically on skin papillomas and on bladder cancers. Alpha1H is a Company's drug candidate for bladder cancer in ongoing phase I/II clinical trials.

Sector

More about the company